Fig. 2.
Long-term (months 3–12) exacerbation rate by reliever use thresholds. Long-term (months 3–12) exacerbation rates for patients receiving a) FORM and b) BUD/FORM with a mean number of inhalations less than, and greater than or equal to, reliever use in the range from zero to 12 inhalations/day in the week preceding the 2-month visit. BUD budesonide, FORM formoterol